Tadalafil Tablet, Film Coated
Product Images NDC 72865-104

This text contains information about Tadalafil tablets, USP, with a dosage of 10 mg. The tablets should not be split, and the entire dose should be taken. The usual dosage information can be found in accompanying literature. The product should be kept out of reach of children and stored at 20° to 25°C. The manufacturer is XLCare Pharmaceuticals, Inc., located in Lawrenceville, GA, while manufacturing is done by Evaric Pharmaceuticals Inc. in Hauppauge, New York. The product is available in packs of 30 tablets and is prescription only. For more information, the U.S. contact number provided is 1-866-495-1995.*

This is the information for XLcare Pharmaceuticals Inc.'s Tadalafil Tablets, USP. Each tablet contains 20 mg of tadalafil. The tablets should not be split, and the entire dose should be taken. It is recommended to store the tablets between 20° to 25°C (68° to 77°F). Keep out of reach of children and dispense in a tight container. For dosage information, refer to the accompanying literature. For inquiries, contact 1-866-495-1995. Address for XLCare Pharmaceuticals, Inc.: 242 South Culver Street, Suite 202, Lawrenceville, GA 30046. Manufactured by Evaric Pharmaceuticals Inc. at 155 Commerce Drive, Hauppauge, New York 11788, United States.*

XLcare Pharmaceuticals Inc. offers Tadalafil tablets, USP 2.5mg for once daily use. Each film-coated tablet contains 2.5 mg of tadalafil USP. The usual dosage is one tablet daily. These tablets should not be split, and the entire dose should be taken. The medication should be kept out of reach of children and stored at 20° to 25°C. The product is available in a pack of 30 tablets. For more information, refer to the accompanying literature or contact 1-866-495-1995 in the US.*

This is a description of Tadalafil Tablets, USP 5 mg produced by XLcare Pharmaceuticals Inc. Each film-coated tablet contains 5 mg of tadalafil USP and should not be split; the entire dose should be taken. The recommended storage condition is between 20° to 25°C (68° to 77°F). The contact number for the U.S. is provided as 1-866-495-1995. It is indicated to refer to accompanying literature for the usual dosage. The tablets should be dispensed in a tight container and kept out of reach of children. The manufacturing address for XLCare Pharmaceuticals, Inc. is 242 South Culver Street, Suite 202, Lawrenceville, GA 30046, and for Evaric Pharmaceuticals Inc. is 155 Commerce Drive, Hauppauge, New York 11788, United States (USA).*

This data appears to show the standing and supine systolic blood pressure levels at different hours post-dose of two different treatments - Tadalafil 20 mg & doxazosin 8 mg, and Placebo & doxazosin 8 mg. The table includes measurements at various time points from 8 to 24 hours post-dose.*

This text gives information about a study comparing the effects of 20 mg tadalafil and placebo in combination with 8 mg doxazosin on systolic blood pressure at different time points. The data suggests that there may be variations in blood pressure based on the treatment and time after administration.*

This text provides information on Plasma Tadalafil Concentration in micrograms per liter (µg/L) over a specific period of time after administering different doses of tadalafil. It shows the concentration levels at different time points ranging from 12 to 120 hours for a single 20-mg tadalafil dose, a single 5-mg tadalafil dose, and once-daily 5-mg tadalafil following 5 consecutive days of administration.*

This description provides information about a study comparing the effects of Tadalafil 5 mg and Placebo on BPH patients. The figure shows the Mean IPSS Changes over the weeks of treatment in Study J.*

This text provides information about a study involving Tadalafil 5 mg and a placebo for BPH patients, showing mean IPSS changes by visit over a duration of treatment in weeks. The study found a statistically significant difference (p<0.01) between the two groups.*

This text provides information on the LS Mean Change from Baseline at 12 and 26 weeks of therapy for Tadalafil/Finasteride compared to Placebo/Finasteride. There is a treatment difference indicated with a p-value of <0.08.*

This text mentions the comparison between Tadalafil and Placebo in terms of their effect on the Change from Baseline in IPSS Total Score over different durations of treatment. The statistical significance of p<0.01 indicates that there is a notable difference between the two groups. Additionally, the mention of treatment duration suggests that this data may be part of a study or clinical trial evaluating the efficacy of these medications for a certain condition.*